Vanguard Group Inc. Has $164.22 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Vanguard Group Inc. reduced its stake in Agios Pharmaceuticals by 0.5%, holding approximately 5.6 million shares worth $164.22 million as of the latest SEC filing.
• Analysts are mixed on AGIO; Wall Street Zen downgraded the stock from "hold" to "sell", while Bank of America lowered its price target but maintained a "buy" rating.
• Agios Pharmaceuticals reported a quarterly earnings per share of ($1.93), missing estimates by $0.19, with revenue of $12.50 million surpassing expectations of $9.46 million.

Vanguard Group Inc. cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 0.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,604,591 shares of the biopharmaceutical company's stock after selling 26,730 shares during the quarter. Vanguard Group Inc. owned 9.68% of Agios Pharmaceuticals worth $164,215,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in AGIO. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $39,000. CWM LLC increased its holdings in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 499 shares during the period. Finally, Summit Investment Advisors Inc. increased its holdings in shares of Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares during the period.

Wall Street Analysts Forecast Growth

AGIO has been the topic of several recent research reports. Scotiabank lowered their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Bank of America reduced their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Up 3.2%

Agios Pharmaceuticals stock traded up $1.20 during mid-day trading on Tuesday, reaching $38.46. The company had a trading volume of 647,317 shares, compared to its average volume of 973,578. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The company has a market cap of $2.23 billion, a P/E ratio of 3.50 and a beta of 0.80. The business has a fifty day simple moving average of $36.93 and a 200 day simple moving average of $32.94.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 1,780 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the sale, the chief financial officer owned 30,049 shares in the company, valued at $1,007,843.46. This trade represents a 5.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Brian Goff sold 11,085 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $36.67, for a total transaction of $406,486.95. Following the completion of the sale, the chief executive officer owned 123,528 shares in the company, valued at $4,529,771.76. This represents a 8.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,448 shares of company stock valued at $2,026,141. Corporate insiders own 4.93% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.